Clinical Trial Update: Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (FibroCAN) is evaluating finerenone for diabetic cardiovascular autonomic neuropathy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Autonomic Neuropathy
• Diabetic Neuropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Finerenone (finerenone)

Snippet

Sponsor: Peter Rossing | Conditions: Cardiovascular Autonomic Neuropathy, Type 2 Diabetes | Phase 2 | Status: RECRUITING